Trial · NCT02652819
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
NCT02652819, Phase 3, Completed, Kyntra Bio
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis. Trials, record NCT02652819. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02652819
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
- NCT number
- NCT02652819
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 154 participants, actual
- Lead sponsor
- Kyntra Bio
- Conditions
- Anemia
- Interventions
- FG-4592, Placebo
- First posted
- 2016-01-12
- Last updated
- 2017-08-24
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Hb from baseline to the average level | Weeks 7 to 9 inclusive. | Change in Hb from baseline to the average level |
| Secondary | The proportion of subjects who achieve a confirmed Hb response | up to and including Week 9 | The proportion of subjects who achieve a confirmed Hb response |
| Secondary | Proportion of subjects with mean Hb ≥10.0 g/dL | Weeks 7 to 9 | Proportion of subjects with mean Hb ≥10.0 g/dL |
| Secondary | Mean change from baseline in low-density lipoprotein (LDL) cholesterol averaged | Weeks 7 to 9 | Mean change from baseline in low-density lipoprotein (LDL) cholesterol averaged |
| Secondary | Effect on iron metabolism | Week 9 | Measurement of serum iron |
| Secondary | Survey (SF-36) Physical Functioning (PF) subscore measured in Week 9 in the Full Analysis Set (FAS) subjects with baseline PF subscore below 35 | Week 9 | Survey (SF-36) Physical Functioning (PF) subscore measured in Week 9 in the Full Analysis Set (FAS) subjects with baseline PF subscore below 35 |
| Secondary | Mean change from baseline in SF-36 vitality subscore measured in Week 9 in FAS subjects with baseline vitality subscore below 50. | Week 9 | Mean change from baseline in SF-36 vitality subscore measured in Week 9 in FAS subjects with baseline vitality subscore below 50. |
| Secondary | Mean change from baseline in mean arterial blood pressure | Weeks 7 to 9 | Mean change from baseline in mean arterial blood pressure |
| Secondary | Proportion of subjects who received rescue therapy (composite of blood transfusion, ESA use, and IV iron) | Up to Week 9 | Proportion of subjects who received rescue therapy (composite of blood transfusion, ESA use, and IV iron) |
| Secondary | Percent of subjects with treatment-emergent adverse events (TEAEs). | Week 1 up to Week 53 | Percent of subjects with treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02652819
GET https://conductscience.org/api/trials/v1/NCT02652819/registered